SEARCH

SEARCH BY CITATION

References

  • 1
    Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004; 12: 96102.
  • 2
    Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005; 102: 92949299.
  • 3
    Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623626
  • 4
    Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791796.
  • 5
    Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938941.
  • 6
    Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004; 78: 14481455.
  • 7
    Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96: 1276612771.
  • 8
    Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 50175025.
  • 9
    Barth H, Cerino R, Arcuri M, Hoffmann M, Schurmann P, Adah MI, et al. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J Virol 2005; 79: 57745785.
  • 10
    Barth H, Schüfer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278: 4100341012.
  • 11
    Smith AE, Helenius A. How viruses enter animal cells. Science 2004; 304: 237242.
  • 12
    Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 2003; 424: 456461.
  • 13
    Weissman D, Rabin RL, Arthos J, Rubbert A, Dybul M, Swofford R, et al. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 1997; 389: 981985.
  • 14
    Cicala C, Arthos J, Selig SM, Dennis G Jr, Hosack DA, Van Ryk D, et al. HIV envelope induces a cascade of cell signals in non-proliferating target cells that favor virus replication. Proc Natl Acad Sci U S A 2002; 99: 93809385.
  • 15
    Steinmann D, Barth H, Gissler B, Schärmann P, Adah MI, Gerlach JT, et al. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 2004; 78: 90309040.
  • 16
    Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 1998; 72: 38273836.
  • 17
    Wellnitz S, Klumpp B, Barth H, Ito S, Depla E, Dubuisson J, et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J Virol 2002; 76: 11811193.
  • 18
    Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005; 105: 36053614.
  • 19
    Donauer J, Rumberger B, Klein M, Faller D, Wilpert J, Sparna T, et al. Expression profiling on chronically rejected transplant kidneys. Transplantation 2003; 76: 539547.
  • 20
    Van Gelder RN, von Zastrow ME, Yool A, Dement WC, Barchas JD, Eberwine JH. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A 1990; 87: 16631667.
  • 21
    Eisen MB, Brown PO. DNA arrays for the analysis of gene expression. Meth Enzymol 1999; 303: 179189.
  • 22
    Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A 2002; 99: 972977.
  • 23
    Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 2001; 29: 365371.
  • 24
    Dudoit S, Young YH, Speed T. Statistical methods for identifying differentially expressed genes in replicated cDNA microarray experiments. Statistica Sinica 2002; 12: 111139.
  • 25
    Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B 1995; 57: 289.
  • 26
    Kaufman L, Rousseeuw P. Finding groups in data: an introduction to cluster analysis. Hoboken, NJ: John Wiley, 1990.
  • 27
    Pfaffl MW. Development and validation of an externally standardised quantitative insulin like growth factor-1 (IGF-1) RT-PCR using LightCycler SYBR® Green I technology. In: MeuerS, WittwerC, NakagawaraK, eds. Rapid Cycle Real-time PCR, Methods and Applications. Heidelberg, Germany: Springer Press, 2001: 281191.
  • 28
    Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A 2002; 99: 1566915674.
  • 29
    Otsuka M, Aizaki H, Kato N, Suzuki T, Miyamura T, Omata M, et al. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem Biophys Res Commun 2003; 300: 443447.
  • 30
    Triyatni M, Saunier B, Maruvada P, Davis AR, Ulianich L, Heller T, et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 2002; 76: 93359344.
  • 31
    Xiang J, Wunschmann S, George SL, Klinzman D, Schmidt WN, LaBrecque DR, et al. Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays. J Med Virol 2002; 68: 537543.
  • 32
    Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633642.
  • 33
    Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 2003; 100: 72717276.
  • 34
    Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 2002; 68: 206215.
  • 35
    Sasaki M, Yamauchi K, Nakanishi T, Kamogawa Y, Hayashi N. In vitro binding of hepatitis C virus to CD81-positive and -negative human cell lines. J Gastroenterol Hepatol 2003; 18: 7479.
  • 36
    Garson JA, Lubach D, Passas J, Whitby K, Grant PR. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J Med Virol 1999; 57: 238242.
  • 37
    Hisaeda K, Inokuchi A, Nakamura T, Iwamoto Y, Kohno K, Kuwano M, et al. Interleukin-1beta represses MRP2 gene expression through inactivation of interferon regulatory factor 3 in HepG2 cells. HEPATOLOGY 2004; 39: 15741582.
  • 38
    Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334342.
  • 39
    Bosserhoff AK, Moser M, Scholmerich J, Buettner R, Hellerbrand C. Specific expression and regulation of the new melanoma inhibitory activity-related gene MIA2 in hepatocytes. J Biol Chem 2003; 278: 1522515231.
  • 40
    Seipp S, Mueller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T. Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol 1997; 78: 24672476.
  • 41
    Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, Mizokami M, et al. Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. J Biol Chem 2004; 279: 2237122376.
  • 42
    Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. J Virol 2001; 75: 70597066.
  • 43
    Biswas PS, Banerjee K, Kim B, Rouse BT. Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. J Immunol 2004; 172: 37363744.
  • 44
    Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3.
  • 45
    Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242: 580583.
  • 46
    Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF, Berglund P, et al. CD8+ T cell cross-priming via transfer of proteasome substrates. Science 2004; 304: 13181321.
  • 47
    Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J Exp Med 1996; 183: 499514.
  • 48
    Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, et al. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 2004; 114: 250259.
  • 49
    Ruibal-Ares BH, Belmonte L, Bare PC, Parodi CM, Massud I, de Bracco MM. HIV-1 infection and chemokine receptor modulation. Curr HIV Res 2004; 2: 3950.
  • 50
    Varani S, Frascaroli G, Homman-Loudiyi M, Feld S, Landini MP, Soderberg-Naucler C. Human cytomegalovirus inhibits the migration of immature dendritic cells by down-regulating cell-surface CCR1 and CCR5. J Leukoc Biol 2005; 77: 219228.
  • 51
    Yasukawa M, Hasegawa A, Sakai I, Ohminami H, Arai J, Kaneko S, et al. Down-regulation of CXCR4 by human herpesvirus 6 (HHV-6) and HHV-7. J Immunol 1999; 162: 54175422.
  • 52
    Shi ST, Polyak SJ, Tu H, Taylor DR, Gretch DR, Lai MM. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 2002; 292: 198210.
  • 53
    Giambartolomei S, Covone F, Levrero M, Balsano C. Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus core protein. Oncogene 2001; 20: 26062610.
  • 54
    Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, et al. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004; 72: 5259.
  • 55
    Lee SH, Kim YK, Kim CS, Seol SK, Kim J, Cho S, et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005; 175: 82268235.
  • 56
    Li K, Prow T, Lemon SM, Beard MR. Cellular response to conditional expression of hepatitis C virus core protein in Huh7 cultured human hepatoma cells. HEPATOLOGY 2002; 35: 12371246.
  • 57
    Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 2001; 97: 10231026.
  • 58
    Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998; 59: 563578.
  • 59
    Asanza CG, Garcia-Monzon C, Clemente G, Salcedo M, Garcia-Buey L, Garcia-Iglesias C, et al. Immunohistochemical evidence of immunopathogenetic mechanisms in chronic hepatitis C recurrence after liver transplantation. HEPATOLOGY 1997; 26: 755763.
  • 60
    Lee S, Park U, Lee YI. Hepatitis C virus core protein transactivates insulin-like growth factor II gene transcription through acting concurrently on Egr1 and Sp1 sites. Virology 2001; 283: 167177.
  • 61
    Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. HEPATOLOGY 2003; 38: 14681476.
  • 62
    Isoyama T, Kuge S, Nomoto A. The core protein of hepatitis C virus is imported into the nucleus by transport receptor Kap123p but inhibits Kap121p-dependent nuclear import of yeast AP1-like transcription factor in yeast cells. J Biol Chem 2002; 277: 3963439641.
  • 63
    Maillard P, Lavergne JP, Siberil S, Faure G, Roohvand F, Petres S, et al. Fcgamma receptor-like activity of hepatitis C virus core protein. J Biol Chem 2004; 279: 24302437.
  • 64
    Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76: 69196928.
  • 65
    Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, et al. Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection. J Infect Dis 2002; 185: 18031807.
  • 66
    Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005; 332: 130144.
  • 67
    Nischalke HD, Nattermann J, Fischer HP, Sauerbruch T, Spengler U, Dumoulin FL. Semiquantitative analysis of intrahepatic CC-chemokine mRNas in chronic hepatitis C. Mediators Inflamm 2004; 13: 357359.
  • 68
    Shackel NA, McGuinness PH, Abbott CA, Gorrell MD, McCaughan GW. Novel differential gene expression in human cirrhosis detected by suppression subtractive hybridization. HEPATOLOGY 2003; 38: 577588.